Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2
Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2
复制标题
拉帕替尼对 2 型神经纤维瘤成人脑膜瘤生长的影响
DOI：
--
复制
发表时间：
2018
影响因子：
3.9
通讯作者：
M. Karajannis
中科院分区：
文献类型：
--
作者：
D. Osorio;Jessica M. Hu;C. Mitchell;J. Allen;J. Stanek;M. Hagiwara;M. Karajannis
表皮生长因子受体EGFR和ErbB2在神经鞘瘤和脑膜瘤中高表达。临床前和临床数据表明，拉帕替尼是一种EGFR/ErbB2抑制剂，对2型神经纤维瘤病患者的前庭神经鞘瘤具有抗肿瘤活性。然而，它对脑膜瘤的抗肿瘤活性尚不清楚。方法我们对接受拉帕替尼治疗的NF2和进行性前庭神经鞘瘤患者进行了回顾性研究(NCT00973739)。我们纳入了至少有一个容量可测量脑膜瘤(>； 0.5cm3)的患者，他们至少接受了5个28天的疗程。患者每天服用拉帕替尼1500 mg。脑膜瘤的反应使用三维MRI体积测量仪进行评估。进行性脑膜瘤的生长和反应分别定义为肿瘤体积较基线改变+ 20%和− 20%。结果8例年龄20~58岁的符合标准的脑膜瘤患者中，17例可评价的脑膜瘤的体积，基线时为61.35亿毫升，治疗中为61.17亿毫升，治疗后为108.86毫升(+ 77.44%变化)，p = 为0.0033。中位治疗时间为15.5个月，停药时间为16.7个月。治疗期间的平均年化增长率和中位数年化增长率分别为10.67%和1.32%。非治疗后的平均和中位数年化增长率分别为20.05%和10.42%。服用拉帕替尼23个月后，容量反应最好的是− 26.1%。两个肿瘤在治疗期间 >； 的体积增加了20%，而8个肿瘤在治疗后增加了20%。结论这些数据表明拉帕替尼可能对NF2患者的脑膜瘤具有生长抑制作用，并支持了拉帕替尼对NF2患者进展性脑膜瘤的前瞻性研究。
IntroductionEpidermal growth factor receptors EGFR and ErbB2 are overexpressed in schwannomas and meningiomas. Preclinical and clinical data indicate that lapatinib, an EGFR/ErbB2 inhibitor, has antitumor activity against vestibular schwannomas in neurofibromatosis type 2 (NF2) patients. Its antitumor activity against meningiomas, however, is unknown.MethodsWe conducted a retrospective review of patients with NF2 and progressive vestibular schwannomas treated on a phase 2 clinical trial with lapatinib (NCT00973739). We included patients with at least one volumetrically measurable meningioma (> 0.5 cm3) who received at least five 28-day courses of treatment. Patients received lapatinib 1500 mg daily. Meningioma response was assessed using 3-dimensional MRI volumetrics. Progressive meningioma growth and response were defined as + 20 and − 20% change in tumor volume from baseline, respectively. Off-treatment was defined as any period > 5 months without lapatinib.ResultsEight patients (ages: 20–58 years) who met criteria had 17 evaluable meningiomas with a combined volume of 61.35 cc at baseline, 61.17 cc during treatment, and 108.86 cc (+ 77.44% change) off-treatment, p = 0.0033. Median time on-treatment and off-treatment was 15.5 and 16.7 months, respectively. On-treatment mean and median annualized growth rates were 10.67 and 1.32%, respectively. Off-treatment mean and median annualized growth rates were 20.05 and 10.42%, respectively. The best volumetric response was − 26.1% after 23 months on lapatinib. Two tumors increased > 20% volumetrically on-treatment, compared to eight tumors off-treatment.ConclusionsThese data suggest that lapatinib may have growth-inhibitory effects on meningiomas in NF2 patients, and support prospective studies of lapatinib for NF2 patients with progressive meningiomas.
影响因子：
28.2
作者：
Vivanco I;Robins HI;Rohle D;Campos C;Grommes C;Nghiemphu PL;Kubek S;Oldrini B;Chheda MG;Yannuzzi N;Tao H;Zhu S;Iwanami A;Kuga D;Dang J;Pedraza A;Brennan CW;Heguy A;Liau LM;Lieberman F;Yung WK;Gilbert MR;Reardon DA;Drappatz J;Wen PY;Lamborn KR;Chang SM;Prados MD;Fine HA;Horvath S;Wu N;Lassman AB;DeAngelis LM;Yong WH;Kuhn JG;Mischel PS;Mehta MP;Cloughesy TF;Mellinghoff IK
通讯作者：
Mellinghoff IK
影响因子：
15.9
作者：
Grommes, Christian;Oxnard, Geoffrey R.;Lassman, Andrew B.
通讯作者：
Lassman, Andrew B.
对神经纤维瘤病 2 基因的分析揭示了脑膜瘤的分子变异。
DOI：
--
发表时间：
1995
期刊：
The American journal of pathology.
影响因子：
--
作者：
Wellenreuther,R;Kraus,JA;Lenartz,D;Menon,AG;Schramm,J;Louis,DN;Ramesh,V;Gusella,JF;Wiestler,OD;vonDeimling,A
通讯作者：
vonDeimling,A